During the first respiratory syncytial virus (RSV) season in which a maternal vaccine and a monoclonal antibody for infants ...

CDC's RSV vaccine recommendations from Pfizer and GSK face review by HHS advisor William "Reyn" Archer III. Read more here.

Moderna MRNA kicked off 2025 with mixed first-quarter results. While its streamlining efforts improved bottom-line numbers, ...

The advisory panel to the Centers for Disease Control and Prevention had made recommendations regarding the use of separate ...

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

“We are proud that ABRYSVO has the broadest indication among RSV vaccines, covering older adults, adults 18 and older at heightened risk of severe disease, and pregnant women to help protect ...

Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to ...